Published in Clin Exp Rheumatol on November 03, 2010
Peripheral neuropathy: a complication of systemic sclerosis. Clin Rheumatol (2013) 0.83
The promising role of lung ultrasound in systemic sclerosis. Clin Rheumatol (2012) 0.76
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Labile exocyclic amine protection of nucleosides in DNA, RNA and oligonucleotide analog synthesis facilitating N-deacylation, minimizing depurination and chain degradation. Biochimie (1993) 2.34
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19
Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in HCV/HIV or HCV infected patients. Haemophilia (2012) 2.00
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil (1997) 1.62
Heart rate variability: an index of brain processing in vegetative state? An artificial intelligence, data mining study. Clin Neurophysiol (2010) 1.52
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat (2013) 1.46
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
The measurement of outcome and the rheumatoid arthritis core set to lift the prejudice of the 'thaumaturgus cliche'. Rheumatology (Oxford) (2006) 1.42
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) (2012) 1.40
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum (2001) 1.39
High free and latent collagenase activity in psoriatic arthritis synovial fluids. Br J Rheumatol (1994) 1.39
Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis. J Intern Med (1992) 1.38
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol (1993) 1.30
Absent innervation of skin and sweat glands in congenital insensitivity to pain with anhidrosis. Clin Neurophysiol (2000) 1.30
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) (2009) 1.29
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci U S A (1991) 1.26
Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford) (2006) 1.24
Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology (2004) 1.23
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis (2010) 1.22
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum (2007) 1.18
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis (2008) 1.13
QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J (2008) 1.13
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum (2001) 1.11
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis (2009) 1.08
Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. Rheumatology (Oxford) (2008) 1.07
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis (2011) 1.05
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis (2010) 1.05
Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach. Ann Rheum Dis (2005) 1.03
Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum (1995) 1.02
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis (2008) 1.00
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis (2008) 0.99
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum (2011) 0.98
NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet (2000) 0.98
Macrophage activation results in bone resorption. Clin Orthop Relat Res (1998) 0.97
Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy. Scand J Rheumatol (1987) 0.97
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum (2011) 0.96
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis (2008) 0.95
Capillaria hepatica infection in wild brown rats (Rattus norvegicus) from the urban area of Milan, Italy. J Vet Med B Infect Dis Vet Public Health (2001) 0.95
Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum (2010) 0.94
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis (2004) 0.94
The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis (SSc) patients. Rheumatol Int (2011) 0.94
Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol (2009) 0.93
Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol (1998) 0.92
Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol (1997) 0.92
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum (1998) 0.92
Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol (1998) 0.91
Huntington's disease: survival of large striatal neurons in the rigid variant. Ann Neurol (1984) 0.91
Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol (2006) 0.91
Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity (1990) 0.91
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis (2007) 0.91
Neuropeptides of the autonomic nervous system in Sjögren's syndrome. Ann Rheum Dis (1997) 0.91
Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis (2002) 0.90
Erectile dysfunction in men with obstructive sleep apnea: an early sign of nerve involvement. Sleep (2000) 0.90
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis (2007) 0.89
Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. Clin Exp Rheumatol (2003) 0.89
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis (2008) 0.89
Surface EMG alterations induced by underwater recording. J Electromyogr Kinesiol (2004) 0.88
The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial. Rheumatol Int (2010) 0.88
Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis (2007) 0.88
Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings. Ann Rheum Dis (2009) 0.88
Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status? Ann Rheum Dis (2005) 0.88
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin (2005) 0.87
Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis (2008) 0.87
Is atrial natriuretic peptide important in the circadian rhythm of arterial blood pressure? Am J Cardiol (1989) 0.87
Circadian rhythm of serum erythropoietin in healthy subjects. Riv Eur Sci Med Farmacol (1997) 0.87
Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol (2001) 0.86
Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia (2012) 0.86
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol (2001) 0.86
Imaging of spondylodiscitis. Eur Rev Med Pharmacol Sci (2012) 0.85
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatology (Oxford) (2006) 0.85
Occupational risk for hematological malignancies. Am J Hematol (1991) 0.84
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford) (2006) 0.84
[Work activities and the risk of multiple myeloma. A case-control study]. Med Lav (1991) 0.84